{"title":"Perioperative direct oral anticoagulant management during cardiac implantable electronic device surgery: an updated systematic review and meta-analysis.","authors":"Chidubem Ezenna, Vinicius Pereira, Mohammed Abozenah, Ancy Jenil Franco, Oghenetejiri Gbegbaje, Ayesha Zaidi, Mrinal Murali Krishna, Meghna Joseph, Prasana Ramesh, Fadi Chalhoub","doi":"10.1007/s10840-024-01947-z","DOIUrl":"https://doi.org/10.1007/s10840-024-01947-z","url":null,"abstract":"<p><strong>Background: </strong>Patients undergoing cardiovascular implantable electronic device (CIED) implantation are often on direct oral anticoagulation (DOAC). However, the evidence on whether to continue or temporarily discontinue DOAC therapy during the perioperative period in these patients is unclear.</p><p><strong>Methods: </strong>We conducted a comprehensive literature review using PubMed, Embase, and Cochrane databases through July 2024. We included studies comparing uninterrupted versus interrupted perioperative DOAC therapy in patients undergoing CIED procedure- primary implants, pulse generator replacement, and device upgrades. Primary outcomes were clinically significant device-pocket hematoma and thromboembolic events. Secondary outcomes included any device-pocket hematoma, all-cause mortality, major bleeding, and any bleeding.</p><p><strong>Results: </strong>A total of 1,607 patients from 8 studies were included. The mean age was 73.2 years, with atrial fibrillation as the indication for DOAC therapy in most patients. The mean CHA2DS2-VASc was 3.4. Among the included studies, 2 were randomized control trials (RCTs), while the others were observational cohort studies, including one that was propensity score matched. Our meta-analysis found both strategies to be similar in terms of clinically significant pocket hematoma (RR 1.70; 95%CI 0.84-3.45; p = 0.14; I<sup>2</sup> = 0%), thromboembolic complications (RR 0.35; 95%CI 0.04-3.32; p = 0.36; I<sup>2</sup> = 19%), any pocket hematoma, all-cause mortality and any bleeding with a higher risk of major bleeding with uninterrupted anticoagulation.</p><p><strong>Conclusion: </strong>This meta-analysis shows that uninterrupted DOAC therapy is comparable to interrupted therapy for CIED procedures, with a potential increase in major bleeding risk but low overall complication rates. Further research is needed to confirm the best approach of periprocedural anticoagulation in these patients.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ulises Rojel Martinez, José Llorente, Nestor López Cabanillas, Luis Ignacio Mondragon, Mauricio Ibrahim Scanavacca, Juan Carlos Zerpa Acosta, William Fernando Bautista Vargas, María Eugenia Santillan, Dulce María García Frias, Armando Perez Silva, Leonardo Onetto, Alexander Dal Forno, Hermes Leonel Morales Molina, Mauricio Abello, Enrique Monjes, Richard Soto Becerra, Alberto Alfie, Juan Carlos Diaz Martinez, Diego Andres Rodríguez Guerrero, Manuel Felipe Patete Ayala, Januário de Pardo Mêo Neto, Silvano Diangelo, Jefferson Jaber, Luis Alberto Wayar Caballero, Edgardo Alfredo Rodriguez Salazar, Gustavo Tortajada, Carina Hardy, Fernando Vidal Bett, Hael Lizandro Fernandez Prado, Elibet Chavez Gonzalez, Luis Fernando Pava, José Enrique Vives Rodríguez, Mauricio Contreras, Lenin Rene Bulnes Garcia, Eric Karabut, Ramón Antonio Requena Dugun, Roberto Keegan
{"title":"The second Latin American catheter ablation registry (\"II LAHRS EP registry\").","authors":"Ulises Rojel Martinez, José Llorente, Nestor López Cabanillas, Luis Ignacio Mondragon, Mauricio Ibrahim Scanavacca, Juan Carlos Zerpa Acosta, William Fernando Bautista Vargas, María Eugenia Santillan, Dulce María García Frias, Armando Perez Silva, Leonardo Onetto, Alexander Dal Forno, Hermes Leonel Morales Molina, Mauricio Abello, Enrique Monjes, Richard Soto Becerra, Alberto Alfie, Juan Carlos Diaz Martinez, Diego Andres Rodríguez Guerrero, Manuel Felipe Patete Ayala, Januário de Pardo Mêo Neto, Silvano Diangelo, Jefferson Jaber, Luis Alberto Wayar Caballero, Edgardo Alfredo Rodriguez Salazar, Gustavo Tortajada, Carina Hardy, Fernando Vidal Bett, Hael Lizandro Fernandez Prado, Elibet Chavez Gonzalez, Luis Fernando Pava, José Enrique Vives Rodríguez, Mauricio Contreras, Lenin Rene Bulnes Garcia, Eric Karabut, Ramón Antonio Requena Dugun, Roberto Keegan","doi":"10.1007/s10840-024-01942-4","DOIUrl":"https://doi.org/10.1007/s10840-024-01942-4","url":null,"abstract":"<p><strong>Background: </strong>Patient's clinical characteristics, technical resources, center and operator volume, and operator experience and training are known variables impacting outcomes. Although international standards have been agreed to maximize the benefits of this therapy, regional and global differences still exist. Latin American information has not been updated in the last 10 years. This study aimed to analyze current information on operators, centers, and CA in Latin America.</p><p><strong>Methods: </strong>Observational, retrospective study collecting Latin American information on operators and centers participating in CA, and procedures performed in 2023, from January 1 to December 31.</p><p><strong>Results: </strong>Electrophysiologists 178 (18 countries). Mean age 46,8 ± 9,2 (28-74) years. Male 86,5%. AFib, VT, and cardioneuroablation were performed by 80,2%, 70,9%, and 35,5% of operators respectively. Centers 175 (17 countries). Private 79,4% and academic 44,0%. Low volume (< 50/year) represented 36,6% and 38,3% performed ≥ 100 ablations/year. Procedures 7.595 (8.284 arrhythmias, 17 countries, 134 centers, 76 electrophysiologists). Patients mean age 51,5 ± 19,3 (1-95) years, male 55,3%, and 77,5% had a structurally normal heart. RF was the energy in 95,6% of procedures, cryoablation in 4,7%, and PFA in 0,2%. The most frequently treated arrhythmias were AFib (28,2%), AVNRT (20,9%), APs (15,8%), and PVC/NSVT (8,3%). Global success and complication rates were 93,6% and 3,0%, respectively and mortality 0,05%.</p><p><strong>Conclusion: </strong>II LAHRS EP Registry brings new and interesting data related to EP in Latin America. Electrophysiologists showed acceptable levels of experience, skills, and qualification. Although centers revealed an under-ideal availability of infrastructure and technical resources, the results of CA were comparable to other registries worldwide.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ilaria My, Boris Schmidt, Laura Rottner, Shota Tohoku, Marc Lemoine, David Schaack, Fabian Moser, Lukas Urbanek, Julius Obergassel, Djemail Ismaili, Jun Hirokami, Paulus Kirchhof, Karin Plank, Bruno Reissmann, Feifan Ouyang, Andreas Rillig, Julian Chun, Andreas Metzner, Stefano Bordignon
{"title":"Radiofrequency balloon ablation: 1-year outcomes of the AURORA study.","authors":"Ilaria My, Boris Schmidt, Laura Rottner, Shota Tohoku, Marc Lemoine, David Schaack, Fabian Moser, Lukas Urbanek, Julius Obergassel, Djemail Ismaili, Jun Hirokami, Paulus Kirchhof, Karin Plank, Bruno Reissmann, Feifan Ouyang, Andreas Rillig, Julian Chun, Andreas Metzner, Stefano Bordignon","doi":"10.1007/s10840-024-01938-0","DOIUrl":"https://doi.org/10.1007/s10840-024-01938-0","url":null,"abstract":"<p><strong>Background: </strong>A novel irrigated radiofrequency balloon (RFB) for pulmonary vein isolation (PVI) integrated into a 3D mapping platform was recently launched.</p><p><strong>Methods: </strong>Patients undergoing a first atrial fibrillation (AF) ablation at two German high-volume EP centers were included into the prospective AURORA registry. All patients underwent clinical follow-up (FU) at 90, 180, and 360 days following ablation including 48-h Holter ECGs.</p><p><strong>Results: </strong>A total of 99 patients were enrolled (43/99 (43.4%) women, median age 67 years (interquartile range [IQR] 59-74), 43/99 (43.4%) persistent AF (Pers-AF), median left ventricular ejection fraction (LVEF) 60% (IQR 62-55)). Eighty-eight patients completed the follow-up. Acute PVI was achieved in 383/383 (100%) PV. Single-shot PVI was achieved in 211/383 (55.1%) PVs. Primary adverse events occurred in 3% of patients (1 postprocedural pharyngeal bleeding, 1 myocardial infarction, 1 non-cardiovascular death); no pericardial effusion, stroke, or phrenic nerve paralysis was observed. Median ablation and procedure times were 23 (IQR 18-32) and 67 (IQR 57-85) min, respectively. Median dose area product was 761 (IQR 509-1534) mGycm<sup>2</sup>. AF-free survival after a median FU of 361 (IQR 261-375) days was 78.4% for paroxysmal AF (PAF) and 75.4% for Pers-AF (p value = 0.828). Early recurrence of atrial tachyarrhythmia at the 90-day visit was the only independent predictor for AF recurrence at 1 year upon multiple regression analysis (hazard ratio [HR] 3.198; 95% confidence interval [95% CI] 1.036-10.32, p value = 0.0433).</p><p><strong>Conclusion: </strong>RFB-based PVI is acutely successful, appears safe, and has comparable rhythm outcomes to other single-shot AF ablation tools. A recurrence of AF at 90 days predicts later AF recurrence.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vera Maslova, Thomas Demming, Robert Pantlik, Tamas Geczy, Peter Falk, Bjoern Andrew Remppis, Derk Frank, Evgeny Lian
{"title":"Omitting transesophageal echocardiography before catheter ablation of atrial fibrillation.","authors":"Vera Maslova, Thomas Demming, Robert Pantlik, Tamas Geczy, Peter Falk, Bjoern Andrew Remppis, Derk Frank, Evgeny Lian","doi":"10.1007/s10840-024-01825-8","DOIUrl":"10.1007/s10840-024-01825-8","url":null,"abstract":"<p><strong>Background: </strong>Data about necessity of performing transesophageal echocardiography (TOE) prior to every catheter ablation (CA) of atrial fibrillation (AF) is scarce. We aimed to evaluate the safety of an individualized risk-based approach to TOE with respect to thromboembolic cerebrovascular events (CVE) in patients undergoing CA for AF or left atrial tachycardia (AT).</p><p><strong>Methods: </strong>We performed a retrospective clinical study based on our institutional registry database. Patients undergoing CA for AF or left-sided AT following initial AF ablation at two participating centers were enrolled. Prior to the procedure, patients were scheduled for TOE only if they had a history of thromboembolic stroke, left atrial appendage (LAA) thrombus, or inappropriate anticoagulation regimen in the previous 3 to 4 weeks. The incidence of periprocedural cerebrovascular thromboembolic events was assessed.</p><p><strong>Results: </strong>We analyzed 1155 patients (median age 70 years, 54.8% male, 48.1% had persistent AF/AT). In 261 patients, a TOE was performed; in 2 patients (0.7%), an LAA thrombus was detected, which led to cancellation of the catheter ablation; in 894 patients, the TOE was omitted. Of the 1153 (0.35%) patients who underwent ablation, 4 (0.35%) experienced a CVE (one TIA and three strokes). The rate of CVE in our study does not exceed that reported in most multicenter trials. The low event rates limited statistical analysis of possible risk factors for CVE. In all 4 patients with CVE, post-CVE imaging showed the absence of LAA thrombus.</p><p><strong>Conclusions: </strong>An individualized selective approach to TOE before catheter ablation of AF or left AT showed a very low risk of overt intraprocedural thromboembolic events for the population in our study. A further randomized controlled study is needed to determine whether TOE prior to catheter ablation without ICE could be omitted in patients with uninterrupted OAC without previous thromboembolic events or a history of left atrial thrombus.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":"1781-1791"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fabienne Kreimer, Katharina Koepsel, Michael Gotzmann, Boldizsar Kovacs, Tobias C Dreher, Christian Blockhaus, Norbert Klein, Thomas Kuntz, Dong-In Shin, Hendrik Lapp, Stephanie Rosenkaimer, Mohammad Abumayyaleh, Nazha Hamdani, Ardan Muammer Saguner, Julia W Erath, Firat Duru, Thomas Beiert, Fabian Schiedat, Christian Weth, Florian Custodis, Ibrahim Akin, Andreas Mügge, Assem Aweimer, Ibrahim El-Battrawy
{"title":"Predictors of ventricular tachyarrhythmia in patients with a wearable cardioverter defibrillator: an international multicenter registry.","authors":"Fabienne Kreimer, Katharina Koepsel, Michael Gotzmann, Boldizsar Kovacs, Tobias C Dreher, Christian Blockhaus, Norbert Klein, Thomas Kuntz, Dong-In Shin, Hendrik Lapp, Stephanie Rosenkaimer, Mohammad Abumayyaleh, Nazha Hamdani, Ardan Muammer Saguner, Julia W Erath, Firat Duru, Thomas Beiert, Fabian Schiedat, Christian Weth, Florian Custodis, Ibrahim Akin, Andreas Mügge, Assem Aweimer, Ibrahim El-Battrawy","doi":"10.1007/s10840-024-01869-w","DOIUrl":"10.1007/s10840-024-01869-w","url":null,"abstract":"<p><strong>Background and aims: </strong>Wearable cardioverter defibrillator (WCD) can protect patients from sudden cardiac death due to ventricular tachyarrhythmias and serve as a bridge to decision of definite defibrillator implantation. The aim of this analysis from an international, multicenter WCD registry was to identify predictors of sustained ventricular tachycardia (VT) and/or ventricular fibrillation (VF) in this population.</p><p><strong>Methods: </strong>One thousand six hundred seventy-five patients with WCD were included in a multicenter registry from 9 European centers, with a median follow-up of 440 days (IQR 120-893). The primary study end point was the occurrence of sustained VT/VF.</p><p><strong>Results: </strong>Sustained VT was detected by WCD in 5.4% and VF in 0.9% of all patients. Of the 30.3% of patients receiving ICD implantation during follow-up, sustained VT was recorded in 9.3% and VF in 2.6%. Non-ischemic cardiomyopathy (HR 0.5, p < 0.001), and medication with angiotensin-converting enzyme inhibitors (HR 0.7, p = 0.027) and aldosterone antagonists (HR 0.7, p = 0.005) were associated with a significantly lower risk of VT/VF.</p><p><strong>Conclusions: </strong>Patients who received WCD due to a transient increased risk of sudden cardiac death have a comparatively lower risk of VT/VF in the presence of non-ischemic cardiomyopathy. Of note, optimal medical treatment for heart failure not only results in an improvement in left ventricular ejection fraction but also in a reduction in the risk for VT/VF.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":"1917-1928"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11606999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benjamin Walters, Michael Farbaniec, Asma Khurseed, Mario D Gonzalez, Gerald V Naccarelli, Ankit Maheshwari
{"title":"Prevalence of left atrial myopathy in people presenting for ablation of cavotricuspid isthmus-dependent right atrial flutter and the risk of developing atrial fibrillation.","authors":"Benjamin Walters, Michael Farbaniec, Asma Khurseed, Mario D Gonzalez, Gerald V Naccarelli, Ankit Maheshwari","doi":"10.1007/s10840-024-01823-w","DOIUrl":"10.1007/s10840-024-01823-w","url":null,"abstract":"","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":"1943-1945"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Single-center experience of efficacy and safety of atrioventricular node ablation after left bundle branch area pacing for the management of atrial fibrillation.","authors":"Mathieu Jacobs, Alexandre Bodin, Pascal Spiesser, Dominique Babuty, Nicolas Clementy, Arnaud Bisson","doi":"10.1007/s10840-024-01847-2","DOIUrl":"10.1007/s10840-024-01847-2","url":null,"abstract":"<p><strong>Background: </strong>Atrioventricular node ablation (AVNA) with permanent pacing is an effective treatment of symptomatic atrial fibrillation (AF). Left bundle branch area pacing (LBBAP) prevents cardiac dyssynchrony associated with right ventricular pacing and could prevent worsening of heart failure (HF).</p><p><strong>Methods: </strong>In this retrospective monocentric study, all patients who received AVNA procedure with LBBAP were consecutively included. AVNA procedure data, electrical and echocardiographic parameters at 6 months, and clinical outcomes at 1 year were studied and compared to a matched cohort of patients who received AVNA procedure with conventional pacing between 2010 and 2023.</p><p><strong>Results: </strong>Seventy-five AVNA procedures associated with LBBAP were studied. AVNA in this context was feasible, with a success rate of 98.7% at first ablation, and safe without any complications. There was no threshold rise at follow-up. At 1 year, 6 (8%) patients were hospitalized for HF and 2 (2.7%) were deceased. Patients had a significant improvement in NYHA class and left ventricular ejection fraction (LVEF) (P ≤ 0.0001). When compared to a matched cohort of patients with AVNA and conventional pacing, AVNA data and pacing complications rates were similar. Patients with LBBAP had a better improvement of LVEF (+5.27 ± 9.62% vs. -0.48 ± 14%, P = 0.01), and a lower 1-year rate of composite outcome of hospitalization for HF or death (HR 0.39, 95% CI: 0.16-0.95, P = 0.037), significant on survival analysis (log-rank P-value = 0.03).</p><p><strong>Conclusion: </strong>AVNA with LBBAP in patients with symptomatic AF is feasible, safe, and efficient. Hospitalization for HF or death rate was significantly lower and LVEF improvement was greater.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":"1865-1876"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Siddharth Agarwal, Kassem Farhat, Muhammad Salman Khan, Christopher V DeSimone, Abhishek Deshmukh, Muhammad Bilal Munir, Zain Ul Abideen Asad, Stavros Stavrakis
{"title":"Sex differences in atrial fibrillation ablation outcomes in patients with heart failure.","authors":"Siddharth Agarwal, Kassem Farhat, Muhammad Salman Khan, Christopher V DeSimone, Abhishek Deshmukh, Muhammad Bilal Munir, Zain Ul Abideen Asad, Stavros Stavrakis","doi":"10.1007/s10840-024-01833-8","DOIUrl":"10.1007/s10840-024-01833-8","url":null,"abstract":"<p><strong>Background: </strong>There is a lack of data on the impact of sex on the outcomes of patients with heart failure (HF) undergoing atrial fibrillation (AF) ablation. We aimed to analyze the association of sex with outcomes of atrial fibrillation ablation in patients with heart failure.</p><p><strong>Methods: </strong>The National Readmissions Database (NRD) was analyzed from 2016 to 2019 to identify patients ≥ 18 years old with heart failure (HF) undergoing AF ablation. The outcomes of interest included peri-procedural complications, in-hospital mortality, resource utilization, and unplanned 1-year readmissions. The final cohort was divided into patients with HFrEF and HFpEF and outcomes were compared between males and females in both cohorts.</p><p><strong>Results: </strong>A total of 23,277 patients with HF underwent AF ablation between 2016 and 2019, of which 14,480 had HFrEF and 8,797 had HFpEF. Among patients with HFrEF, 61.6% were males and 38.4% were females whereas, among patients with HFpEF, 35.4% were males and 64.6% were females. On a multivariable-adjusted analysis, in patients with HFrEF, there was no difference in the odds of in-hospital mortality, peri-procedural complications, or 1-year HF-related/AF-related/all-cause readmissions between males and females. In patients with HFpEF, females had a higher risk 1-year HF-related readmissions (adjusted hazards ratio: 1.46; 95% CI: 1.13-1.87; p = 0.01), without any difference in the 1-year AF-related/all-cause readmissions, in-hospital mortality, or peri-procedural complications.</p><p><strong>Conclusion: </strong>Our results show that females with HFrEF undergoing AF ablation have similar outcomes whereas females with HFpEF have higher 1-year HF readmissions with no difference in the other outcomes, compared to males.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":"1807-1819"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}